Collectively, these data suggests that the PD1-PDL1 axis can inhibit CAR T cell function in GBM treatment in vivo, and PD1 blockade with anti-PD1 Abs can overcome that inhibition in peripheral disease. Here, CD274 is linked to glioblastoma.